Alder BioPharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference

Globe Newswire 31-Dec-2018 8:00 AM

BOTHELL, Wash., Dec. 31, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that Bob Azelby, Alder's president and chief executive officer, will provide a business overview and update at the 37^th Annual J.P. Morgan Healthcare Conference at 8:00 am PT on Tuesday, January 8, 2019 in San Francisco, CA.

Both the presentation and question and answer session that follows at 8:30 am PT will be webcast live on the Events & Presentations page of the Investors section of Alder's website at http://www.alderbio.com, or by following the links below in your web browser. An archived replay of each webcast will be available on Alder's website for at least 30 days after each live event concludes.

• Presentation Link: https://jpmorgan.metameetings.net/events/healthcare19/sessions/23825-alder-biopharmaceuticals-inc/webcast
• Q&A Link: https://jpmorgan.metameetings.net/events/healthcare19/sessions/24145-alder-biopharmaceuticals-inc-q-a/webcast

About Alder BioPharmaceuticals, Inc.
Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company focused on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Alder's lead product candidate, eptinezumab, is a monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. Unlike other CGRP inhibitors, eptinezumab was specifically designed as an infusion therapy to address significant patient need. Alder is also developing ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) for migraine prevention. For more information, please visit www.alderbio.com.

Investor Relations Contact:                                        
Michael Schaffzin
Stern Investor Relations, Inc.
212.362.1200
michael@sternir.com

Media Contact: 
Ashley Cadle
TogoRun
a.cadle@togorun.com
310.463.0143